Trevi Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Trevi Therapeutics (TRVI).

Price Target Range — 11 Quarters

Analyst Consensus — 15 Analysts

1S.Buy

14Buy

Consensus RatingBuy# Analysts15Avg. Consensus PT$22Upside to Avg. PT+72.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 14, 2026	Jones Trading	Debanjana Chatterjee	PT Raise	Buy	$24→$28
Aug 7, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform	$24→$25
Aug 7, 2026	Cantor Fitzgerald	Josh Schimmer	PT Raise	Overweight	$25→$30
Jul 21, 2026	BMO Capital	Connor Murphy	Initiate	Outperform	$36
Jul 20, 2026	B. Riley Securities	Mayank Mamtani	PT Raise	Buy	$21→$31
Jul 20, 2026	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$21→$24
May 20, 2026	Needham	Serge Belanger	Maintained	Buy	$23
May 6, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$21
May 6, 2026	Needham	Serge Belanger	PT Cut	Buy	$24→$23
Apr 17, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$19
Mar 19, 2026	Jones Trading	Debanjana Chatterjee	PT Cut	Buy	$25→$24
Mar 18, 2026	Morgan Stanley	Judah Frommer	PT Cut	Overweight	$19→$18
Mar 18, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$19
Mar 18, 2026	Needham	Serge Belanger	PT Raise	Buy	$22→$24
Mar 9, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$19
Mar 9, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$21
Jan 9, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$21
Jan 8, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$19
Dec 19, 2025	Stifel	Annabel Samimy	PT Raise	Buy	$15→$18
Nov 20, 2025	Leerink Partners	Faisal Khurshid	PT Raise	Outperform	$13→$16

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28

Jones Trading analyst Debanjana Chatterjee maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $24 to $28.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25

Oppenheimer analyst Leland Gershell maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and raises the price target from $24 to $25.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30

Cantor Fitzgerald analyst Josh Schimmer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and raises the price target from $25 to $30.

Benzinga Newsdesk

This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday

Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.

Avi Kapoor

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.

Avi Kapoor

PRO
BMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36

BMO Capital analyst Connor Murphy initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Outperform rating and announces Price Target of $36.

Benzinga Newsdesk

Trevi Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Trevi Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28

PRO
Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25

PRO
Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30

This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PRO
BMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36

People Also Watch

People Also Watch

Trevi Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Trevi Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28

PROOppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25

PROCantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30

This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PROBMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36

People Also Watch

People Also Watch

PRO
Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28

PRO
Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25

PRO
Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30

PRO
BMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36